Objective The purpose of this study was to assess the therapeutic efficacy of molecular
targeted therapies following nivolumab in metastatic renal cell carcinoma and to examine …

The aim of the present study was to evaluate the prognosis of Japanese patients with
metastatic renal cell carcinoma (mRCC) receiving nivolumab and to identify factors …

Objectives To compare the efficacy of nivolumab with that of molecular‐targeted therapy as
a second‐line therapy for metastatic renal cell carcinoma using real‐world data. Methods …

Background The aim of this study was to compare the efficacy and safety of nivolumab as
second-line and later-line (third-line or thereafter) therapy in metastatic renal cell carcinoma …

330 Background: Immune checkpoint inhibitors (ICIs) in combination with another ICI or an
antiangiogenic targeted therapy have been approved for frontline therapy in metastatic renal …

Background In a phase III clinical trial, CheckMate 025, treatment of metastatic renal cell
carcinoma (mRCC) with nivolumab demonstrated superior efficacy over everolimus …

Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune
checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed …

Simple Summary We evaluated the efficacy and safety of molecular-targeted therapies
(MTTs) in 29 patients who discontinued the combination therapy of nivolumab plus …

Background Nivolumab plus ipilimumab combination therapy is one of the standard
therapies for untreated renal cell carcinoma patients with an International Metastatic Renal …

Background/Aim: Nivolumab monotherapy for advanced/metastatic renal cell carcinoma
(RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses …